Forte Biosciences, Inc.

Forte Biosciences, Inc. is currently considered overvalued due to negative financial metrics, including a Price to Book Value of 1.94 and a negative ROE of -113.76%, alongside poor performance compared to peers and a year-to-date return of -43.81%.

As of June 20, 2025, the technical trend is mildly bullish, supported by weekly and monthly MACD and KST indicators, despite some caution from daily moving averages and mixed signals from Bollinger Bands.

As of March 2022, the management team of Forte Biosciences, Inc. is led by Dr. Paul Wagner as Chairman, President, and CEO, with the board of directors including Mr. Thomas Darcy, Dr. Lawrence Eichenfield, Mr. Steven Kornfeld, Dr. Patricia Walker, and Mr. Donald Williams.

Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company developing live biotherapeutics for inflammatory skin diseases, particularly pediatric atopic dermatitis. It operates in the micro-cap market with a market cap of $81.50 million and reported a net profit loss of $16 million as of March 2025.

As of Jun 18, Forte Biosciences, Inc. has a market capitalization of 81.50 million and reported net sales of 0.00 million with a net profit of -43.72 million over the last four quarters. The balance sheet shows shareholder's funds of 52.48 million and total assets of 61.56 million.